Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
June 20, 2018
Oncobiologics Announces Conversion of Majority of Series A Convertible Preferred Stock
CRANBURY, N.J., June 20, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (ONS) (the “Company”) today announced that GMS Tenshi Holdings Pte. Limited (“GMS Tenshi”), the Company’s ...
June 20, 2018
Cormedix Inc. Completes Review and Source Verification of Phase 3 Lock-It 100 Data For Neutrolin(R)
BERKELEY HEIGHTS, NJ / ACCESSWIRE / June 20, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products ...
June 20, 2018
Paratek Announces FDA Advisory Committee Date for Omadacycline
BOSTON, June 20, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon ...
June 20, 2018
Neovasc Announces First Implant of a Neovasc Reducer™ in a U.S. Patient
VANCOUVER , June 20, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter ...
June 20, 2018
Zosano Announces Publication on Adhesive Dermally-Applied Microarray (ADAM™) Technology for the Delivery of Zolmitriptan in Migraine in Journal of Pharmaceutics
FREMONT, Calif., June 20, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration ...
June 19, 2018
Kuros Biosciences to Present Promising Clinical Case Studies with MagnetOs at Leading Spine Surgery Conference
SCHLIEREN (ZURICH), Switzerland, June 19, 2018 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX:KURN) will this week present results from several investigator-led clinical case studies of MagnetOs ...
June 19, 2018
Celyad Doses First AML Patient at Final Dose Level in CYAD-01 THINK Trial and Begins Dosing First Patient With Second Cycle of Therapy
MONT-SAINT-GUIBERT, Belgium, June 19, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell ...
June 19, 2018
MediWound Expands Its NexoBrid® Phase 3 Children Innovation Debridement Study (CIDS) to the U.S.
YAVNE, Israel, June 19, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn ...
June 19, 2018
Novus Therapeutics Receives FDA Guidance at Type C Meeting for OP-02 in the Treatment and Prevention of Otitis Media
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), ...
June 19, 2018
Catalyst Biosciences to Present at the JMP Securities 2018 Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address ...
June 19, 2018
CymaBay Therapeutics to Host Analyst and Investor Day on June 26, 2018
NEWARK, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic ...
June 19, 2018
STRATA Skin Sciences Announces 510(k) Submission for its Multi Micro Dose™ Tip Accessory for the XTRAC® 308nm Excimer Laser
HORSHAM, Pa., June 19, 2018 (GLOBE NEWSWIRE) -- STRATA Skin Sciences (SSKN) (“STRATA”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, ...
June 19, 2018
Avenue Therapeutics to Participate in JMP Securities Life Sciences Conference
NEW YORK, June 19, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous ...
June 19, 2018
Fortress Biotech Announces Publication of Phase 1 Data on CNDO-109-Activated Allogeneic Natural Killer Cells in Acute Myeloid Leukemia in Biology of Blood and Marrow Transplantation
NEW YORK, June 19, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech (FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology ...
June 18, 2018
Innate Pharma to participate in the Citi 2018 European Healthcare Conference on June 20, 2018
Marseille, France, June 18, 2018, 07:00 AM CEST - Innate Pharma (the "Company" - Euronext Paris: FR0010331421 - IPH) today announces that it will be present ...
June 18, 2018
Arcturus Therapeutics to Present at the JMP Securities Life Sciences Conference
SAN DIEGO, June 18, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (ARCT), a leading RNA medicines company, today announced that it plans to present at ...
June 18, 2018
Galmed Pharmaceuticals Ltd. Announces Proposed Public Offering of Ordinary Shares
TEL AVIV, Israel, June 18, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of ...
June 18, 2018
Catalyst Biosciences Provides Update on CB 2679d/ISU304 Factor IX Clinical Program in Hemophilia B
SOUTH SAN FRANCISCO, Calif., June 18, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address ...
June 18, 2018
Arrowhead Completes Enrollment in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it has completed enrollment of a Phase 1 clinical study of ARO-AAT, the company’s second generation ...
June 18, 2018
Caelum Biosciences Announces Presentation of Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis at American Society of Echocardiography 29th Annual Scientific Sessions
NEW YORK, June 18, 2018 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. (FBIO) Company developing treatments for rare and life-threatening diseases, ...
Page 41 of 127